MXPA03010451A - Nuevos metodos para el tratamiento y prevencion del dolor. - Google Patents

Nuevos metodos para el tratamiento y prevencion del dolor.

Info

Publication number
MXPA03010451A
MXPA03010451A MXPA03010451A MXPA03010451A MXPA03010451A MX PA03010451 A MXPA03010451 A MX PA03010451A MX PA03010451 A MXPA03010451 A MX PA03010451A MX PA03010451 A MXPA03010451 A MX PA03010451A MX PA03010451 A MXPA03010451 A MX PA03010451A
Authority
MX
Mexico
Prior art keywords
pain
prevention
stress
treatment
protein kinase
Prior art date
Application number
MXPA03010451A
Other languages
English (en)
Inventor
L Hudkins Robert
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MXPA03010451A publication Critical patent/MXPA03010451A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se presentan nuevos metodos para el tratamiento y/o prevencion del dolor. Los metodos pueden comprender administrar a un sujeto que lo necesite una cantidad efectiva de un inhibidor de quinasa de proteina activada contra estres. Los compuestos preferidos para su uso en los metodos incluyen compuestos de pirrolocarbazola fusionada.
MXPA03010451A 2001-05-16 2002-05-16 Nuevos metodos para el tratamiento y prevencion del dolor. MXPA03010451A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29122701P 2001-05-16 2001-05-16
US10/146,680 US7018999B2 (en) 2001-05-16 2002-05-15 Methods for the treatment and prevention of pain
PCT/US2002/015667 WO2002092065A2 (en) 2001-05-16 2002-05-16 Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors

Publications (1)

Publication Number Publication Date
MXPA03010451A true MXPA03010451A (es) 2004-05-05

Family

ID=26844179

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010451A MXPA03010451A (es) 2001-05-16 2002-05-16 Nuevos metodos para el tratamiento y prevencion del dolor.

Country Status (13)

Country Link
US (1) US7018999B2 (es)
EP (1) EP1389100B1 (es)
JP (1) JP2004534751A (es)
AR (1) AR035971A1 (es)
AT (1) ATE410201T1 (es)
AU (1) AU2002342715A1 (es)
CA (1) CA2447091C (es)
DE (1) DE60229233D1 (es)
DK (1) DK1389100T3 (es)
ES (1) ES2314101T3 (es)
HK (1) HK1062806A1 (es)
MX (1) MXPA03010451A (es)
WO (1) WO2002092065A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241779B2 (en) 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
CN104016992B (zh) 2008-11-19 2017-04-12 赛福伦公司 吲唑并[5,4‑a]吡咯并[3,4‑c]咔唑化合物的形式

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1381031A (en) 1920-01-19 1921-06-07 Thompson James Dumping-wagon
EP0303697B1 (en) 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
WO1993008809A1 (en) 1991-11-08 1993-05-13 The University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
US5621101A (en) 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
CA2163904C (en) 1993-05-28 2000-01-25 Craig A. Dionne Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US6514745B1 (en) 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
US5534426A (en) 1993-07-19 1996-07-09 The Regents Of The University Of California Oncoprotein protein kinase
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5599808A (en) 1994-02-18 1997-02-04 Cephalon, Inc. Aqueous indolocarbazole solutions
US5594009A (en) 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US6046208A (en) 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US5616724A (en) 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
DE69715862T2 (de) 1996-06-25 2003-04-10 Cephalon Inc Verwendung eines k-252a derivats zur behandlung von periphärer oder zentraler nervenerkrankungen und übermässiger cytokinbildung
DK1044203T3 (da) 1997-12-31 2003-07-14 Cephalon Inc 3'-epimere K-252a-derivater
WO1999053927A1 (en) 1998-04-17 1999-10-28 Trustees Of Tufts College Methods for treating and preventing insulin resistance and related disorders
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
GB9811624D0 (en) 1998-05-29 1998-07-29 Merck Sharp & Dohme Therapeutic use
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
EA200500934A1 (ru) 1998-08-26 2006-04-28 Сефалон, Инк. Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
KR20010101266A (ko) 1998-12-17 2001-11-14 프리돌린 클라우스너, 롤란드 비. 보레르 Ｊｎｋ 단백질 키나제의 억제제로서의 4-아릴옥신돌
TR200101747T2 (tr) 1998-12-17 2001-11-21 F.Hoffmann-La Roche Ag 4- ve 5-alkinil oksindoller ve 4- ve 5-alkeniloksindoller.
CN1158283C (zh) 1998-12-17 2004-07-21 霍夫曼-拉罗奇有限公司 作为蛋白激酶抑制剂的4-和5-吡嗪基羟吲哚
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
ATE425142T1 (de) 1999-04-23 2009-03-15 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
AU5316900A (en) 1999-06-03 2000-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
WO2001001986A1 (en) 1999-07-02 2001-01-11 Lipton Stuart A Method of reducing neuronal injury or apoptosis
HUP0202319A3 (en) 1999-07-16 2004-12-28 Warner Lambert Co Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
AU6909600A (en) 1999-08-13 2001-03-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1218347A1 (en) 1999-08-19 2002-07-03 Signal Pharmaceuticals, Inc. Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
CA2410475A1 (en) 2000-06-01 2001-12-06 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
WO2002038035A2 (en) 2000-11-08 2002-05-16 The General Hospital Corporation Methods for inhibiting pain
ES2307667T3 (es) 2000-12-05 2008-12-01 Vertex Pharmaceuticals Incorporated Inhibidires de quinasas terminales c-jun(jnk) y otras proteinas quinasas.

Also Published As

Publication number Publication date
ES2314101T3 (es) 2009-03-16
HK1062806A1 (en) 2004-11-26
DK1389100T3 (da) 2008-12-08
US20030087899A1 (en) 2003-05-08
JP2004534751A (ja) 2004-11-18
ATE410201T1 (de) 2008-10-15
EP1389100B1 (en) 2008-10-08
WO2002092065A2 (en) 2002-11-21
EP1389100A2 (en) 2004-02-18
AR035971A1 (es) 2004-07-28
AU2002342715A1 (en) 2002-11-25
US7018999B2 (en) 2006-03-28
CA2447091C (en) 2012-03-27
WO2002092065A3 (en) 2003-07-31
CA2447091A1 (en) 2002-11-21
DE60229233D1 (de) 2008-11-20

Similar Documents

Publication Publication Date Title
HK1079426A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
ATE247117T1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
ATE321048T1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und - tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
MY151032A (en) Treatment of tnf? related disorders
WO2003089457A3 (en) Peptide inhibitors of protein kinase c ϝ for pain management
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
HRP20050572A2 (en) Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
WO2004016741A3 (en) Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use
MXPA03010451A (es) Nuevos metodos para el tratamiento y prevencion del dolor.
IL139144A0 (en) Mycobacterial inhibitors
AU9545701A (en) Use of carp inhibitors for the treatment of heart diseases
AU2003291368A8 (en) Compounds for the treatment of tobacco dependence and withdrawal
ZA9711468B (en) New use of comt inhibitors
ATE296631T1 (de) Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation
BR9708037A (pt) Método para o tratamento de abuso de substância
ZA200007494B (en) Use of inhibitors of protein kinase C epsilon to treat pain.
PL375354A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
AU2003294697A8 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
AU2002249232A1 (en) Use of $g(g)-gt inhibitors for the treatment of degenerative diseases

Legal Events

Date Code Title Description
FG Grant or registration